Indeed, studies analysing drug responsiveness in ZNF384- and MLL/KMT2A-childhood ALL [5, 55], suggested that FLT3 targeting therapy could be considered in these forms of leukaemia, especially in ZNF384-ALL. This evidence concerns the gene ZNF384 and acute lymphoblastic leukemia.